Khiron Life Sciences Past Earnings Performance
Past criteria checks 0/6
Khiron Life Sciences's earnings have been declining at an average annual rate of -14.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 46.6% per year.
Key information
-14.8%
Earnings growth rate
16.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 46.6% |
| Return on equity | -113.1% |
| Net Margin | -190.0% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Khiron Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 16 | -31 | 22 | 2 |
| 30 Jun 22 | 16 | -30 | 23 | 2 |
| 31 Mar 22 | 15 | -33 | 25 | 1 |
| 31 Dec 21 | 13 | -33 | 26 | 1 |
| 30 Sep 21 | 12 | -16 | 26 | 1 |
| 30 Jun 21 | 10 | -19 | 27 | 1 |
| 31 Mar 21 | 9 | -20 | 27 | 1 |
| 31 Dec 20 | 8 | -24 | 29 | 2 |
| 30 Sep 20 | 8 | -30 | 32 | 2 |
| 30 Jun 20 | 9 | -34 | 36 | 3 |
| 31 Mar 20 | 9 | -38 | 37 | 4 |
| 31 Dec 19 | 10 | -36 | 35 | 4 |
| 30 Sep 19 | 8 | -35 | 31 | 3 |
| 30 Jun 19 | 5 | -29 | 25 | 3 |
| 31 Mar 19 | 3 | -26 | 23 | 1 |
| 31 Dec 18 | 1 | -20 | 19 | 0 |
| 30 Sep 18 | 0 | -16 | 15 | 0 |
| 30 Jun 18 | 0 | -12 | 11 | 0 |
| 31 Mar 18 | 0 | -6 | 6 | 0 |
Quality Earnings: 4KH is currently unprofitable.
Growing Profit Margin: 4KH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4KH is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.
Accelerating Growth: Unable to compare 4KH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4KH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 4KH has a negative Return on Equity (-113.12%), as it is currently unprofitable.